Novartis plans to use a medical device-like sales model to market its CAR T-cell technology if the experimental cancer treatment receives FDA approval, the head of its gene therapy program said.
That strategy may help stem concern about the therapy's complicated distribution process as well as the anticipated high prices for treatment.
The drugmaker has said it plans to file a biologics license application for the therapy, CTL019, with the FDA early next year for an indication for pediatric acute lymphoblastic leukemia, an orphan disease, before seeking expanded indications for to adult lymphoma and other cancers.
That strategy may help stem concern about the therapy's complicated distribution process as well as the anticipated high prices for treatment.
The drugmaker has said it plans to file a biologics license application for the therapy, CTL019, with the FDA early next year for an indication for pediatric acute lymphoblastic leukemia, an orphan disease, before seeking expanded indications for to adult lymphoma and other cancers.
